Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.
about
Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysisMolecular prognostic prediction in liver cirrhosisAdvances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinomaUtilization of hepatocellular carcinoma surveillance among American patients: a systematic reviewReview article: the management of autoimmune hepatitis beyond consensus guidelinesHepatocellular Cancer: New Kids on the BlockPrevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesBiological networks for predicting chemical hepatocarcinogenicity using gene expression data from treated mice and relevance across human and rat speciesImpact of rural residence and health system structure on quality of liver careFacility- and Patient-Level Factors Associated with Esophageal Variceal Screening in the USA.New paradigm for management of hepatocellular carcinoma by imaging.Survival of patients with hepatocellular carcinoma in the San Joaquin Valley: a comparison with California Cancer Registry data.An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis.Improved Outcomes Following Hepatocellular Carcinoma (HCC) Diagnosis in Patients Screened for HCC in a Large Academic Liver Center versus Patients Identified in the Community.Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis.Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factorsCost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.Earlier presentation and application of curative treatments in hepatocellular carcinoma.Updates in the management of hepatocellular carcinomaSurvival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection.Racial, social, and clinical determinants of hepatocellular carcinoma surveillanceRole of surveillance in prevention of hepatocellular carcinoma.Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis.Effects of statins on the risk of hepatocellular carcinomaA rare cause for acute cor pulmonale.Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providersThe effectiveness of ultrasound surveillance for hepatocellular carcinoma in a Canadian centre and determinants of its successImproved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study.Hepatitis C virus-induced hepatocellular carcinomaHepatocellular carcinoma surveillance rates in commercially insured patients with noncirrhotic chronic hepatitis B.Impact of hepatitis C virus eradication on hepatocellular carcinogenesis.Risk of liver cancer among US male veterans with cirrhosis, 1969-1996Failure rates in the hepatocellular carcinoma surveillance process.Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B.Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States
P2860
Q21144594-50528A97-92EA-477E-94F4-1F0D4E20F978Q26784251-D637EB33-0772-4184-9EE5-0EDD0734B620Q26795529-8E508E15-1BAD-4F38-BA95-27EA1605C3CCQ26852154-B449B39F-0E63-4616-AACE-21ED0BDD3D72Q26864272-4FF5B596-302F-4AF7-BF10-A1EA44C62BCFQ27022642-F90FD71F-BADB-4ACD-B7A8-97E5D54291EAQ28272678-2ABDB60F-2179-4F18-9EBB-0A961C2CB29BQ28533447-BDA5676C-DB86-4468-B0B3-3B4F331BF6C8Q28538020-013F9E42-D336-4981-92E0-1E8857420272Q30366707-1CD4CF52-77B2-40D0-945E-5BA85E4D0BC6Q30448048-14FFB133-2066-4174-BDF8-63441FDF63C6Q30796694-B31447E8-85E0-4ECD-A8AB-88CD940B3BDDQ33436257-427739E6-1C5E-429D-AECA-602300B198F1Q33621628-D678A561-8534-4983-A760-9A6C9E2CE234Q33648955-091190F6-4F5C-414E-9217-4B56329A93F4Q33686038-01EA90B2-671C-4AB1-B1B1-6A904CC91721Q33716634-847F97DE-D768-4B8A-A656-78CB97326BB5Q33920344-ED1250E7-9359-46BD-8A0B-49F75D9E50E6Q34137291-7EB6A3DE-9797-4763-9FFD-6BE168E92BECQ34214476-8487779A-BB9D-4264-B4C3-416DEFAEAAD0Q34416067-2E13B891-DB04-4B44-82C1-599B308CC554Q34571160-A05BEB45-9B66-4297-B14A-0CD3F8F89B62Q34618740-370EE865-87A2-45A4-930A-2B917C2389BFQ34808945-2235725C-B669-4B41-83A9-FF2C5D733DB9Q34826014-1F96B7A5-E6DF-42E4-A95D-9B670C8C5EC5Q34902635-2A22FB2F-1F23-42C9-806E-53F8D7FC4CBFQ34997752-D22DA881-DC9A-485B-BCF6-ACC7190415C7Q35071365-71453EF0-E3D6-448B-AB15-A2876C21C83EQ35178251-AD4F30A5-4CF1-46EB-BB9C-EE166D98C2F7Q35613914-195CF13C-C48C-4CC2-8E86-45583789334AQ35690151-22E0EE76-6B6B-4B2A-B786-453C52B69253Q35742671-DE23C800-B5A0-4C21-B018-C708CF58D728Q35785156-0E1CCD7B-9CBD-4822-9E72-C7BA68066F2AQ35824057-1AE9013A-4164-42C6-BD24-3417A928AA1DQ35836354-1A590AC9-1901-4AD5-B7A0-793E61B422BFQ35985401-7C67307C-AD62-480B-91D7-345A5C007B8BQ36075198-D48C7EE9-E92E-4D2E-9659-BAC7B1AB77BCQ36213610-7F70ECA6-8444-44B2-9D01-EEFD4B25939EQ36229496-88E6ED0B-35DD-4E6E-8CD4-F640523A13F0Q36540044-051F66B4-A6EB-4B26-9CEB-DFE9A1B55A7E
P2860
Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of surveillance for hepato ...... irrhosis in the United States.
@en
Use of surveillance for hepato ...... irrhosis in the United States.
@nl
type
label
Use of surveillance for hepato ...... irrhosis in the United States.
@en
Use of surveillance for hepato ...... irrhosis in the United States.
@nl
prefLabel
Use of surveillance for hepato ...... irrhosis in the United States.
@en
Use of surveillance for hepato ...... irrhosis in the United States.
@nl
P2093
P2860
P921
P356
P1433
P1476
Use of surveillance for hepato ...... irrhosis in the United States.
@en
P2093
Hashem B El-Serag
Jessica A Davila
Katherine A McGlynn
Peter A Richardson
Robert O Morgan
Xianglin L Du
P2860
P304
P356
10.1002/HEP.23615
P407
P577
2010-07-01T00:00:00Z